Cart summary

You have no items in your shopping cart.

Methyl eugenol

SKU: orb1221654

Description

Methyleugenol (ME) is a natural constituent of the essential oils of a number of plants widely used in foodstuffs as flavouring agents, in view of the carcinogenic potential of ME, the need to check its presence in food products with effective analytical methods. Methyleugenol has insecticidal properties. Methyleugenol can inhibit the production of nitric oxide and decreased the protein expression of inducible nitric oxide synthase, it down-regulates the production of pro-inflammatory cytokines in the ischemic brain as well as in immunostimulated mixed glial cells; indicates that methyleugenol could be useful for the treatment of ischemia/inflammation-related diseases. Methyleugenol has cytotoxicity and genotoxicity. Intravenous (i.v.) treatment with methyleugenol (ME) in either anesthetized or conscious rats elicits hypotension, an effect that seems related to an active vascular relaxation rather than withdrawal of sympathetic tone. Methyleugenol has antinociceptive effect on the second phase of formalin-induced pain, may be due to the inhibition of N-methyl-d-aspartic acid (NMDA) receptor-mediated hyperalgesia via GABA(A) receptors. Methyleugenol has elaxant and antispasmodic actions on guinea-pig isolated ileum.

Images & Validation

Key Properties

CAS Number93-15-2
MW178.23
Purity>98% (HPLC)
FormulaC11H14O2
SMILESCOC1=C(C=C(C=C1)CC=C)OC
TargetWnt/beta/catenin
SolubilityIn Vitro: DMSO : 100 mg/mL (561.07 mM)

Bioactivity

In Vivo
Animal model: Adult Wistar rats (Rattus norvegicus) model of intestinal ischemia/reperfusion injury. Dosage: 100 mg/kg. Administration: Oral intubation; Once daily for 30 days. Before underwent laparotomy with SMA occlusion 30 min of ischemia followed by 60 min of reperfusion. Result: Significantly decreased the elevated LDH, MDA, and NO levels and concurrently increased the antioxidant biomarkers under test in the intestinal tissue. Significantly downregulate the mRNA expression levels of TNF-α and IL-6.
In Vitro
Cell Autophagy Assay Cell line: RB355 (Human retinoblastoma cells). Concentration: 50 μM. Incubation time: 24 h. Result: Significantly increased the expression of LC3-II in a dose-dependent manner and decreased the expression of p62.Weakened the inhibitory effect of the autophagy inhibitor gastrostatin. Western blot analysis. Cell line: RB355 (Human retinoblastoma cells). Concentration: 50 μM. Incubation time: 48 h. Result: Inhibited the PI3K/mTOR/Akt signaling pathway. Down-regulated the expression of m-TOR and pm-TOR proteins in a concentration-dependent manner. Down-regulated the expression of PI3K/Akt protein.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

Methyleugenol | Methyl eugenol | Eugenol methyl ether

Similar Products

Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Methyl eugenol (orb1221654)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%